[1] 王明国, 王中和.表皮生长因子受体[J].国外医学分子生物学分册, 2002, 24 (2) ∶82-85.
|
[2]Specter M, Nguyen VA, Sheng X.et al.Activation of mitogenacti-vated protein kinase is required for alpha 1-adrenergic agonist-in-duced cell scattering in transfected HepG2 cells[J].Exp Cell Res, 2000, 258 (1) ∶109-200.
|
[3]刘平, Dominique B.肝癌发生过程中转录因子AP-1活化的研究[J].南京医科大学学报, 2004, 24 (1) ∶28-30.
|
[4]张颖超, 韩喜春, 贾明库, 等.癌基因c-fos和c-jun在肝细胞型肝癌中的表达及临床意义[J].吉林大学学报医学版, 2002, 28 (1) ∶46-48.
|
[5]袁芳平, 黄陪生, 龚实华, 等.肝细胞癌c-fos的表达及其与乙型肝炎病毒的关系[J].福建医科大学学报, 1999, 33 (4) ∶365-368.
|
[6]王洛权, 阚秀, 吴秉铨, 等.肝炎病毒和肝癌变的分子病理学进展[J].中华病理学杂志, 1995, 24 (6) ∶393-395.
|
[7]Miyazaki M, Mars W M, Runge D, et al.Phenobarbital suppresses-growth and accelerates restoration ofdiferentiation markers of primaryculture rat hepatacycles in the chemically defined hepatocyte growthmedium containiing hepatacyte growth factor and epidermal growthfactor[J].Exp Cell Res, 1998, 241 (2) ∶445-457.
|
[8]徐标, 韩春荣.槲皮素对血吸虫肝纤维化小鼠肝组织c-fos、c-jun mRNA和转化生长因子β1表达的抑制作用[J].中草药, 2006, 37 (3) ∶393-398.
|
[1] | Xuan QIU, Lijuan CHEN, Ying JIANG, Wei LIU. Hepatocellular carcinoma with constitutional indocyanine green excretory defect: A case report[J]. Journal of Clinical Hepatology, 2021, 37(4): 914-915. doi: 10.3969/j.issn.1001-5256.2021.04.039 |
[2] | Bo Lun, Zhang Qiong, Wang XiangXu, Pan Wei, Zhang HongMei. Role of the VEGF/VEGFR pathways in the development,progression,and treatment of cholangiocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1866-1869. doi: 10.3969/j.issn.1001-5256.2020.08.041 |
[3] | Asia-Pacific Association of Image-Guided Therapy of Oncology,Committee of Minimally Invasive Therapy in Oncology, Chinese Anti-Cancer Association,Asian Conference on Tumor Ablation 2017. Minimally-invasive and multidisciplinary comprehensive diagnosis and treatment for HCC: 2018 Guangzhou consensus[J]. Journal of Clinical Hepatology, 2019, 35(10): 2176-2184. doi: 10.3969/j.issn.1001-5256.2019.10.009 |
[4] | Liao WeiRong, Gu Chao, Zhang DaWei. Clinical efficacy of sorafenib in treatment of primary hepatic carcinoma and its effects on serum VEGFR-2 and PLGF levels[J]. Journal of Clinical Hepatology, 2018, 34(6): 1220-1224. doi: 10.3969/j.issn.1001-5256.2018.06.018 |
[5] | Shao Xin, Gu ChunYan. Expression and significance of P27 and skp2 proteins in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2009, 25(2): 120-121. |
[6] | Zhang RongGui, Tang ZhengHao, Feng Jie, Zang GuoQing, Yu YongSheng. The expression of c-myb in HCC tissues and clinical significance.[J]. Journal of Clinical Hepatology, 2008, 24(2): 106-108. |
[7] | Guo XiaoLin, Jiang YaQiu, Chi BaoRong. The clinical significance of C-myc and P16 gene's expression in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2007, 23(6): 440-441. |
[9] | Ling YunFeng, Feng ZhenBo, He RuKun, Lu: ZiLi. Expression of TGFβ1、TGFβRⅠ and TGFβRⅡ in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2005, 21(1): 35-37. |
[10] | Zhou Hui, Ma YingJi, Yang BaoShan, Zhu SiHe. Clinical evaluation of serum vascular endothelial growth factor and Insulin-like growth factor-Ⅱ assay in the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2004, 20(2): 106-107. |
[11] | Chen Wei, Deng XiaoLing, Cai MeiYing, Wei DaPeng. Expression of TAP and HLA-Ⅰ antigens in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2003, 19(3): 152-153. |